ReviewFrontiers in rehabilitation sciences2026
Neurosurgery to restore function in cerebral palsy: current practice and emerging therapies.
Review in Frontiers in rehabilitation sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral palsy (CP) affects 1.5-2.5 per 1,000 live births and manifests as diverse movement disorders including spasticity, dystonia, and mixed phenotypes that significantly impact motor function and quality of life. This review examines surgical and neuromodulatory interventions for medically refractory CP-associated movement disorders. Selective dorsal rhizotomy (SDR) offers a novel treatment option for spastic diplegia in ambulatory children (GMFCS II-III), with combined dorsal-ventral rhizotomy showing promise for mixed presentations. Peripheral neurectomies provide targeted focal spasticity management with sustained improvements in muscle tone and walking speed. Intrathecal baclofen (ITB) effectively reduces spasticity and dystonia through programmable drug delivery, though infection rates and potential scoliosis progression require monitoring. Deep brain stimulation (DBS) targeting the globus pallidus internus demonstrates efficacy for dystonia-predominant CP, with younger patients showing greater improvement. Emerging cerebellar DBS approaches show early promise for spasticity and mixed presentations. Spinal cord stimulation (SCS) may benefit select patients with spasticity or painful dystonia, though evidence remains limited. Focused ultrasound represents a novel noninvasive ablative option currently under investigation. Treatment selection requires multidisciplinary evaluation considering movement disorder phenotype, functional goals, patient age, and family factors. As understanding of CP pathophysiology advances, mechanism-based, individualized treatment algorithms will increasingly optimize functional outcomes for this heterogeneous patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.